EU agency backs Pfizer leukaemia drug
LONDON Jan 18 (Reuters) - The European Medicines Agency on Friday recommended approval of Pfizer's new pill for a rare type of leukaemia, Bosulif, in a fresh boost for the U.S. drugmaker's cancer business.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- White House reverses, says Obama met uncle and lived with him during law school
- Flights delayed as air pollution hits record in Shanghai
- South Africa mourns Mandela, will bury him on December 15 |
- Analysis: Boeing bidders dangle goodies to win 777X jetliner
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image